Amedisys Inc. Files 8-K Report

TL;DR

AMED filed an 8-K, looks like standard procedure, no major news yet.

AI Summary

On August 7, 2025, Amedisys Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of information. No specific transactions, financial figures, or new material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing signifies a regulatory update from Amedisys Inc., requiring investors and stakeholders to monitor for any disclosed material events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no immediately disclosed material events or financial changes, indicating low immediate risk.

Key Players & Entities

• AMEDISYS INC (company) — Registrant
• August 7, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 11-3131700 (ein) — IRS Employer Identification No.
• 3854 American Way , Suite A , Baton Rouge , LA 70816 (address) — Address of principal executive offices
• (225) 292-2031 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share AMED The NASDAQ Global Se

Filing Documents

• d18915d8k.htm (8-K) — 26KB
• g18915g0807092255161.jpg (GRAPHIC) — 2KB
• 0001193125-25-175190.txt ( ) — 144KB
• amed-20250807.xsd (EX-101.SCH) — 3KB
• amed-20250807_lab.xml (EX-101.LAB) — 18KB
• amed-20250807_pre.xml (EX-101.PRE) — 11KB
• d18915d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Commission File Number: 0-24260 Amedisys, Inc. (Exact name of registrant as specified in charter) Delaware 11-3131700 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 3854 American Way , Suite A , Baton Rouge , LA 70816 (Address of principal executive offices, including zip code) (225) 292-2031 or (800) 467-2662 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2 below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AMED The NASDAQ Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item8.01 Other Events On August 7, 2025, the U.S. Department of Justice (the "DOJ") along with the Attorneys General of Maryland, Illinois, New Jersey, and New York (collectively, the "States") filed a proposed final judgment (the "Proposed Final Judgment") with the U.S. District Court for the District of Maryland (the "Court"). The Proposed Final Judgment was agreed to by Amedisys, Inc. ("Amedisys") and UnitedHealth Group Incorporated ("UnitedHealth Group"). The Proposed Final Judgment would, if approved, resolve the DOJ's and the States' opposition to the previously announced merger transaction (the "Merger") contemplated under the Agreement and Plan of Merger, dated June 26, 2023 (as modified by the waiver dated December 26, 2024, the "Merger Agreement"), by and among UnitedHealth Group, Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group, and Amedisys. The Proposed Final Judgment would, if approved, require the parties to, among other things, carry out certain divestitures within 75 days of the Court's entry of an Asset Preservation/Hold Separate Stipulation and Order or within 60 days of receipt of all necessary merger clearances under Indiana and West Virginia law, whichever is later. The Proposed Final Judgment is subject to judicial approval under the Antitrust Procedures and Penalties Act, 15 U.S.C. 16, for the limited purpose of determining whether the Proposed Final Judgment is in the public interest. Completion of the Merger remains subject to certain conditions to the closing of the transactions contemplated by the Merger Agreement, as specified therein. Cautionary Statement Regarding Forward-Looking Statements This communication may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include projections as to the anticipated benefits of the Merger as well as statements regarding the impact of the Merger on UnitedHealth Group's and Amedisys' business and future financial and operating results, the amount and timing of synergies from the Merger and the closing date for the Merger. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of Amedisys' business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict an

View Full Filing

View this 8-K filing on SEC EDGAR